查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404679

微生物 API 市場規模、佔有率、趨勢分析報告：按宿主、按類型、按位置、按分子、按最終用途、按地區、細分市場預測，2023-2030 年

Microbial API Market Size, Share & Trends Analysis Report By Hose (Mammalian, Bacterial, Fungal), By Type (Antibody, Peptide, Protein), By Site, By Molecule, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

微生物 API 市場成長與趨勢：

Grand View Research最新報告顯示，預計到2030年，全球微生物原料藥市場規模將達到961.1億美元，2023年至2030年複合年成長率為6.66%。

這種成長是由對可治療危及生命的疾病的抗體、蛋白質、小分子和相關產品的需求不斷成長所推動的。此外，增加生產創新疫苗和聯合療法的研發工作預計將推動市場成長。

微生物經過發酵以產生次級代謝物。這些微生物能夠將經濟的碳源（澱粉、葡萄糖、蔗糖）和氮源（棉籽粉、大豆粉、蛋白腖）轉化為有用的中間體和微生物原料藥（維生素、抗生素、胺基酸等）。環境有調整。 API是藥物中的生物/合成活性成分，用於治療、檢測、緩解和預防中樞神經系統疾病、糖尿病、腫瘤、神經系統疾病、心血管疾病和呼吸系統疾病等疾病。原料藥的製造技術包括化學合成、重組DNA、發酵、分離及天然物回收。

對於失去排他性的小分子和生技藥品，製藥公司面臨高昂的定價壓力、競爭加劇和價格邊際收益下降。活性藥物原料藥是所有成品藥的治療核心，佔小分子藥品總成本的 30%，生物相似藥和學名藥的成本高達 55%。因此，原料藥製造商不斷面臨提高性能同時降低價格的挑戰。

儘管微生物發酵有著悠久的歷史，但它對於製藥公司來說是一種高效且經濟的縮短生產時間的手段。發酵過程與現代分子生物學技術和基因工程工具相結合，提高了藥物的安全性和有效性。分子生物學和合成生物學不斷進步的舉措對創新生物合成途徑的發展產生了重大影響。此外，微生物發酵技術不僅在製藥工業中得到應用，而且在食品生產、生物催化酶、農業和其他各個領域都有應用。

市場參與者正在做出策略性努力，以滿足對高效、有效的藥物製劑製造能力不斷成長的需求。市場參與者正專注於開拓新產品和收購區域參與者，以加強其在區域市場的地位。例如，Cytovance Biologics 於 2023 年 3 月與 Phenotype 合作開發了一種釀酒酵母菌株。此次合作預計將加強生物製藥製造並提高生技藥品的生產效率。此類舉措預計將推動微生物 API 市場的整體成長。

微生物 API 市場報告亮點

  • 根據宿主，哺乳動物細分市場將在 2022 年佔據市場主導地位，預計在預測期內將以最快的複合年成長率成長。微生物 API 因其在治療性抗體開發中的有效性和安全性已得到證實而被廣泛採用。
  • 按類型分類，由於對基於抗體的治療藥物開發的需求不斷成長，抗體細分市場將在 2022 年佔據主導市場佔有率。
  • 按地點分類，由於藥物開發中 CDMO 和 CMO 的聘用不斷增加，外包產業在 2022 年的銷售額中佔據最大佔有率。
  • 亞太地區擁有高品質的原料藥生產設施，使該地區在微生物 API 市場中佔據了強勢地位。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢及展望
  • 市場動態
    • 慢性病盛行率增加
    • 對生物來源製品、胺基酸和抗生素的需求增加
    • 加大醫藥產業投資力度
    • 分子生物學和合成生物學的進展
  • 市場抑制因素分析
    • 與程序相關的高成本
  • 2022 年普及與成長前景圖
  • 營商環境分析
    • SWOT 分析；按因素（政治/法律、經濟/技術）
    • 波特五力分析

第4章 主機業務分析

  • 微生物 API 市場：宿主變異分析
  • 哺乳動物的
  • 細菌
  • 菌

第5章 類型業務分析

  • 微生物 API 市場：類型變異分析
  • 抗體
  • 胜肽
  • 蛋白質
  • 低分子
  • 疫苗

第6章基礎業務分析

  • 微生物 API 市場：基礎變化分析
  • 公司內部
  • 外包

第7章 最終用途業務分析

  • 微生物 API 市場：最終用途變化分析
  • 製藥公司
  • 生物製藥公司
  • 其他

第8章分子商業分析

  • 微生物 API 市場：分子變異分析
  • 創新的
  • 非專利的

第9章區域業務分析

  • 2022 年和 2030 年按地區分類的微生物 API市場佔有率
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第10章競爭形勢

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 合夥
    • 獲得
    • 合作
    • 資金籌措
  • 2022年主要企業市場佔有率分析
  • 企業熱力圖分析
  • 公司簡介
    • MERCK &CO., INC.
    • Topfond Pharmaceutical Co., Ltd.
    • DSM
    • CSPC Pharmaceutical Group Limited
    • KOLON LIFE SCIENCE
    • Shandong Lukang Pharmaceutical Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Lonza
Product Code: GVR-4-68040-156-1

Microbial API Market Growth & Trends:

The global microbial API market size is anticipated to reach USD 96.11 billion by 2030 and display a CAGR of 6.66% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to the rising demand for antibodies, proteins, small molecules, and related products capable of treating life-threatening diseases. Furthermore, an increase in R&D efforts for the manufacturing of innovative vaccines and combined therapy is anticipated to propel the market growth.

Microorganisms undergo fermentation for the development of secondary metabolites. Adjustments in growth environments are made to enable these organisms to covert economical carbon sources (starch, glucose, sucrose) and nitrogen sources (cotton-seed flour, soybean flour, peptone) into useful intermediates or microbial APIs (such as vitamins, antibiotics, amino acids). APIs are the biological/synthetic active constituents of pharmaceuticals and are used to treat, detect, mitigate, and prevent diseases, including conditions such as CNS disorders, diabetes, oncology, neurological diseases, cardiovascular and respiratory disorders, and others. Some of the production techniques used for the manufacture of API include chemical synthesis, recombinant DNA, fermentation, isolation, and natural source recovery.

There is high pricing pressure, increased competition, and declining pricing margins faced by pharma companies for small molecules and biologics that have lost exclusivity. APIs, which are the therapeutic core of every finished medicinal product, account for 30% of total drug product expenses for small molecules and up to 55% for biosimilar and generics. As a result, API manufacturers are always challenged to increase performance while lowering prices.

While microbial fermentation has been in existence for a long time, it offers pharmaceutical companies an efficient and cost-effective means to reduce production timelines. When combined with contemporary molecular biology techniques and genetic engineering tools, the fermentation process enhances the safety and efficacy of medicines. Rising initiatives for advancements in molecular biology and synthetic biology have had a profound effect on the development of innovative biosynthetic pathways. Moreover, microbial fermentation techniques find applications not only in the pharmaceutical industry but also in sectors such as food production, bio catalytic enzymes, agriculture, and various other fields.

Market players are undertaking strategic initiatives to address the growing demand for efficient and effective drug formulation manufacturing capacity. Players in the market are focusing on developing new products and acquisition of regional players to strengthen their position in the regional market. For instance, in March 2023, Cytovance Biologics entered into a partnership with Phenotypeca for the development of the saccharomyces cerevisiae strain. The partnership is expected to enhance biopharmaceutical manufacturing and improve biologics production efficiency. Such initiatives are expected to propel the overall growth of the microbial API market.

Microbial API Market Report Highlights:

  • Based on host, the mammalian segment dominated the market in 2022 and is expected to grow at the fastest CAGR over the forecast period, as microbial APIs are widely adopted due to their proven efficacy and safety profile for the development of therapeutic antibodies
  • Based on type, the antibody segment held the dominant market share in 2022 due to the rising need to develop antibody-based therapeutics
  • Based on site, the outsourced segment held the largest revenue share in 2022, owing to the rising adoption of CDMOs and CMOs for drug development
  • Asia Pacific has established a strong regional position in the market for microbial API due to the presence of manufacturing facilities for high-quality APIs in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing prevalence of chronic conditions
    • 3.4.2. Increased demand for biological products, amino acids, and antibiotics
    • 3.4.3. Increasing investment in the pharmaceutical industry
    • 3.4.4. Advances in molecular biology and synthetic biology
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost associated with the procedure
  • 3.6. Penetration and Growth Prospect Mapping 2022
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.7.2. Porter's Five Forces Analysis

Chapter 4. Host Business Analysis

  • 4.1. Microbial API Market: Host Movement Analysis
  • 4.2. Mammalian
    • 4.2.1. Mammalian Market, 2018 - 2030 (USD Million)
  • 4.3. Bacterial
    • 4.3.1. Bacterial Market, 2018 - 2030 (USD Million)
  • 4.4. Fungal
    • 4.4.1. Fungal Market, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Microbial API Market: Type Movement Analysis
  • 5.2. Antibody
    • 5.2.1. Antibody Market, 2018 - 2030 (USD Million)
  • 5.3. Peptide
    • 5.3.1. Peptide Market, 2018 - 2030 (USD Million)
  • 5.4. Protein
    • 5.4.1. Protein Market, 2018 - 2030 (USD Million)
  • 5.5. Small Molecule
    • 5.5.1. Small Molecule Market, 2018 - 2030 (USD Million)
  • 5.6. Vaccine
    • 5.6.1. Vaccine Market, 2018 - 2030 (USD Million)

Chapter 6. Site Business Analysis

  • 6.1. Microbial API Market: Site Movement Analysis
  • 6.2. In-house
    • 6.2.1. In-house Market, 2018 - 2030 (USD Million)
  • 6.3. Outsourced
    • 6.3.1. Outsourced Market, 2018 - 2030 (USD Million)

Chapter 7. End-use Business Analysis

  • 7.1. Microbial API Market: End-use Movement Analysis
  • 7.2. Pharmaceutical Companies
    • 7.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 7.3. Biopharmaceutical Companies
    • 7.3.1. Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 7.4. Others
    • 7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Molecule Business Analysis

  • 8.1. Microbial API Market: Molecule Movement Analysis
  • 8.2. Innovative
    • 8.2.1. Innovative Market, 2018 - 2030 (USD Million)
  • 8.3. Generic
    • 8.3.1. Generic Market, 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis

  • 9.1. Microbial API Market Share By Region, 2022 & 2030
  • 9.2. North America
    • 9.2.1. SWOT Analysis
    • 9.2.2. North America Microbial API Market, 2018 - 2030 (USD Million)
    • 9.2.3. U.S.
      • 9.2.3.1. Key Country Dynamics
      • 9.2.3.2. Target Disease Prevalence
      • 9.2.3.3. Competitive Scenario
      • 9.2.3.4. Regulatory Framework
      • 9.2.3.5. Reimbursement Scenario
      • 9.2.3.6. U.S. Microbial API Market, 2018 - 2030 (USD MILLION)
    • 9.2.4. Canada
      • 9.2.4.1. Key Country Dynamics
      • 9.2.4.2. Target Disease Prevalence
      • 9.2.4.3. Competitive Scenario
      • 9.2.4.4. Regulatory Framework
      • 9.2.4.5. Reimbursement Scenario
      • 9.2.4.6. Canada Microbial API Market, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. SWOT Analysis
    • 9.3.2. Europe Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Target Disease Prevalence
      • 9.3.3.3. Competitive Scenario
      • 9.3.3.4. Regulatory Framework
      • 9.3.3.5. Reimbursement Scenario
      • 9.3.3.6. Germany Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.4. UK
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Target Disease Prevalence
      • 9.3.4.3. Competitive Scenario
      • 9.3.4.4. Regulatory Framework
      • 9.3.4.5. Reimbursement Scenario
      • 9.3.4.6. UK Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.5. France
      • 9.3.5.1. Key Country Dynamics
      • 9.3.5.2. Target Disease Prevalence
      • 9.3.5.3. Competitive Scenario
      • 9.3.5.4. Regulatory Framework
      • 9.3.5.5. Reimbursement Scenario
      • 9.3.5.6. France Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.6. Italy
      • 9.3.6.1. Key Country Dynamics
      • 9.3.6.2. Target Disease Prevalence
      • 9.3.6.3. Competitive Scenario
      • 9.3.6.4. Regulatory Framework
      • 9.3.6.5. Reimbursement Scenario
      • 9.3.6.6. Italy Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.7. Spain
      • 9.3.7.1. Key Country Dynamics
      • 9.3.7.2. Target Disease Prevalence
      • 9.3.7.3. Competitive Scenario
      • 9.3.7.4. Regulatory Framework
      • 9.3.7.5. Reimbursement Scenario
      • 9.3.7.6. Spain Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.8. Denmark
      • 9.3.8.1. Key Country Dynamics
      • 9.3.8.2. Target Disease Prevalence
      • 9.3.8.3. Competitive Scenario
      • 9.3.8.4. Regulatory Framework
      • 9.3.8.5. Reimbursement Scenario
      • 9.3.8.6. Denmark Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.9. Sweden
      • 9.3.9.1. Key Country Dynamics
      • 9.3.9.2. Target Disease Prevalence
      • 9.3.9.3. Competitive Scenario
      • 9.3.9.4. Regulatory Framework
      • 9.3.9.5. Reimbursement Scenario
      • 9.3.9.6. Sweden Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.10. Norway
      • 9.3.10.1. Key Country Dynamics
      • 9.3.10.2. Target Disease Prevalence
      • 9.3.10.3. Competitive Scenario
      • 9.3.10.4. Regulatory Framework
      • 9.3.10.5. Reimbursement Scenario
      • 9.3.10.6. Norway Microbial API Market, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. SWOT Analysis
    • 9.4.2. Asia Pacific Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.3. Japan
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Competitive Scenario
      • 9.4.3.4. Regulatory Framework
      • 9.4.3.5. Reimbursement Scenario
      • 9.4.3.6. Japan Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.4. China
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Competitive Scenario
      • 9.4.4.4. Regulatory Framework
      • 9.4.4.5. Reimbursement Scenario
      • 9.4.4.6. China Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.5. India
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Target Disease Prevalence
      • 9.4.5.3. Competitive Scenario
      • 9.4.5.4. Regulatory Framework
      • 9.4.5.5. Reimbursement Scenario
      • 9.4.5.6. India Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.6. South Korea
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Target Disease Prevalence
      • 9.4.6.3. Competitive Scenario
      • 9.4.6.4. Regulatory Framework
      • 9.4.6.5. Reimbursement Scenario
      • 9.4.6.6. South Korea Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.7. Australia
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Target Disease Prevalence
      • 9.4.7.3. Competitive Scenario
      • 9.4.7.4. Regulatory Framework
      • 9.4.7.5. Reimbursement Scenario
      • 9.4.7.6. Australia Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.8. Thailand
      • 9.4.8.1. Key Country Dynamics
      • 9.4.8.2. Target Disease Prevalence
      • 9.4.8.3. Competitive Scenario
      • 9.4.8.4. Regulatory Framework
      • 9.4.8.5. Reimbursement Scenario
      • 9.4.8.6. Thailand Microbial API Market, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. SWOT Analysis
    • 9.5.2. Latin America Microbial API Market, 2018 - 2030 (USD Million)
    • 9.5.3. Brazil
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Competitive Scenario
      • 9.5.3.4. Regulatory Framework
      • 9.5.3.5. Reimbursement Scenario
      • 9.5.3.6. Brazil Microbial API Market, 2018 - 2030 (USD Million)
    • 9.5.4. Mexico
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Target Disease Prevalence
      • 9.5.4.3. Competitive Scenario
      • 9.5.4.4. Regulatory Framework
      • 9.5.4.5. Reimbursement Scenario
      • 9.5.4.6. Mexico Microbial API Market, 2018 - 2030 (USD Million)
    • 9.5.5. Argentina
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Target Disease Prevalence
      • 9.5.5.3. Competitive Scenario
      • 9.5.5.4. Regulatory Framework
      • 9.5.5.5. Reimbursement Scenario
      • 9.5.5.6. Argentina Microbial API Market, 2018 - 2030 (USD Million)
  • 9.6. MEA
    • 9.6.1. SWOT Analysis
    • 9.6.2. MEA Microbial API Market, 2018 - 2030 (USD Million)
    • 9.6.3. South Africa
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Competitive Scenario
      • 9.6.3.4. Regulatory Framework
      • 9.6.3.5. Reimbursement Scenario
      • 9.6.3.6. South Africa Microbial API Market, 2018 - 2030 (USD Million)
    • 9.6.4. Saudi Arabia
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Competitive Scenario
      • 9.6.4.4. Regulatory Framework
      • 9.6.4.5. Reimbursement Scenario
      • 9.6.4.6. Saudi Arabia Microbial API Market, 2018 - 2030 (USD Million)
    • 9.6.5. UAE
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Competitive Scenario
      • 9.6.5.4. Regulatory Framework
      • 9.6.5.5. Reimbursement Scenario
      • 9.6.5.6. UAE Microbial API Market, 2018 - 2030 (USD Million)
    • 9.6.6. Kuwait
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Target Disease Prevalence
      • 9.6.6.3. Competitive Scenario
      • 9.6.6.4. Regulatory Framework
      • 9.6.6.5. Reimbursement Scenario
      • 9.6.6.6. Kuwait Microbial API Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Strategy Mapping
    • 10.2.1. New Product Launch
    • 10.2.2. Partnerships
    • 10.2.3. Acquisition
    • 10.2.4. Collaboration
    • 10.2.5. Funding
  • 10.3. Key Company Market Share Analysis, 2022
  • 10.4. Company Heat Map Analysis
  • 10.5. Company Profiles
    • 10.5.1. MERCK & CO., INC.
      • 10.5.1.1. Company overview
      • 10.5.1.2. Financial performance
      • 10.5.1.3. Product benchmarking
      • 10.5.1.4. Strategic initiatives
    • 10.5.2. Topfond Pharmaceutical Co., Ltd.
      • 10.5.2.1. Company overview
      • 10.5.2.2. Financial performance
      • 10.5.2.3. Product benchmarking
      • 10.5.2.4. Strategic initiatives
    • 10.5.3. DSM
      • 10.5.3.1. Company overview
      • 10.5.3.2. Financial performance
      • 10.5.3.3. Product benchmarking
      • 10.5.3.4. Strategic initiatives
    • 10.5.4. CSPC Pharmaceutical Group Limited
      • 10.5.4.1. Company overview
      • 10.5.4.2. Financial performance
      • 10.5.4.3. Product benchmarking
      • 10.5.4.4. Strategic initiatives
    • 10.5.5. KOLON LIFE SCIENCE
      • 10.5.5.1. Company overview
      • 10.5.5.2. Financial performance
      • 10.5.5.3. Product benchmarking
      • 10.5.5.4. Strategic initiatives
    • 10.5.6. Shandong Lukang Pharmaceutical Co., Ltd.
      • 10.5.6.1. Company overview
      • 10.5.6.2. Financial performance
      • 10.5.6.3. Product benchmarking
      • 10.5.6.4. Strategic initiatives
    • 10.5.7. Teva Pharmaceutical Industries Ltd.
      • 10.5.7.1. Company overview
      • 10.5.7.2. Financial performance
      • 10.5.7.3. Product benchmarking
      • 10.5.7.4. Strategic initiatives
    • 10.5.8. Lonza
      • 10.5.8.1. Company overview
      • 10.5.8.2. Financial performance
      • 10.5.8.3. Product benchmarking
      • 10.5.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 3 Global Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 5 Global Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 6 Global Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 7 Global Microbial API Market, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Microbial API Market, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 10 North America Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 North America Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 12 North America Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 13 North America Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 14 U.S. Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 15 U.S. Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 16 U.S. Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 17 U.S. Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 18 U.S. Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 19 Canada Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 20 Canada Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Canada Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 22 Canada Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 23 Canada Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 24 Europe Microbial API Market, by Country, 2018 - 2030 (USD Million)
  • Table 25 Europe Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 26 Europe Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Europe Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 28 Europe Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 29 Europe Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 30 Germany Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 31 Germany Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 32 Germany Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 33 Germany Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 34 Germany Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 35 UK Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 36 UK Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 37 UK Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 38 UK Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 39 UK Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 40 France Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 41 France Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 France Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 43 France Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 44 France Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 45 Italy Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 46 Italy Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 Italy Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 48 Italy Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 49 Italy Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 50 Spain Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 51 Spain Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Spain Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 53 Spain Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 54 Spain Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 55 Denmark Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 56 Denmark Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 57 Denmark Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 58 Denmark Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 59 Denmark Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 60 Sweden Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 61 Sweden Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 62 Sweden Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 63 Sweden Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 64 Sweden Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 65 Norway Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 66 Norway Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Norway Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 68 Norway Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 69 Norway Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific Microbial API Market, by Country, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 76 China Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 77 China Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 78 China Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 79 China Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 80 China Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 81 Japan Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 82 Japan Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Japan Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 84 Japan Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 85 Japan Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 86 India Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 87 India Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 India Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 89 India Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 90 India Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 91 South Korea Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 92 South Korea Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 South Korea Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 94 South Korea Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 95 South Korea Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 96 Australia Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 97 Australia Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 98 Australia Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 99 Australia Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 100 Australia Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 101 Thailand Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 102 Thailand Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 103 Thailand Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 104 Thailand Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 105 Thailand Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 106 Latin America Microbial API Market, by Country, 2018 - 2030 (USD Million)
  • Table 107 Latin America Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 108 Latin America Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 109 Latin America Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 110 Latin America Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 111 Latin America Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 112 Brazil Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 113 Brazil Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 114 Brazil Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 115 Brazil Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 116 Brazil Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 117 Mexico Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 118 Mexico Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 119 Mexico Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 120 Mexico Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 121 Mexico Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 122 Argentina Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 123 Argentina Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 124 Argentina Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 125 Argentina Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 126 Argentina Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 127 Middle East & Africa Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 128 Middle East & Africa Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 129 Middle East & Africa Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 130 Middle East & Africa Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 131 Middle East & Africa Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 132 South Africa Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 133 South Africa Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 134 South Africa Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 135 South Africa Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 136 South Africa Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 137 Saudi Arabia Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 138 Saudi Arabia Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 142 UAE Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 143 UAE Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 144 UAE Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 145 UAE Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 146 UAE Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 147 Kuwait Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 148 Kuwait Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 149 Kuwait Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 150 Kuwait Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 151 Kuwait Microbial API Market, by Molecule, 2018 - 2030 (USD Million)